Sign in

You're signed outSign in or to get full access.

Evelyn D’An

Director at Zoomcar Holdings
Board

About Evelyn D’An

Evelyn D’An is an independent director of Zoomcar Holdings, Inc. (ZCAR), serving since December 2023 and currently designated as a Class III director whose term expires at the 2026 annual meeting. She is a former Ernst & Young audit partner with over 18 years of client service across technology, retail, and consumer sectors, holds a B.S. in Accounting from SUNY Albany, and previously was a licensed CPA in New York (from July 9, 1990). She chairs Zoomcar’s Audit Committee and is recognized by the Board as an “audit committee financial expert.”

Past Roles

OrganizationRoleTenureCommittees/Impact
Ernst & YoungAudit Partner18+ yearsLed audits across tech, retail, consumer products; deep financial reporting expertise
Enochian Biosciences (NASDAQ: ENOB)DirectorMar 2018 – Apr 2021Audit; Nominating & Governance; Compensation
Summer Infant, Inc. (NASDAQ, sold Jun 2022)DirectorNov 2016 – Jun 2022Chaired Compensation; member Audit; company sold to private buyer

External Roles

OrganizationRoleTenureCommittees/Impact
Backblaze, Inc. (NASDAQ: BLZE)DirectorAug 2021 – presentChairs Audit; member Compensation
GHD Group Pty LtdDirectorMar 2020 – presentChairs Audit; member Global I&D Council and Risk Committee
NACD FloridaBoard ChairCurrentGovernance thought leadership; frequent governance speaker

Board Governance

  • Independence: The Board determined D’An is independent under Nasdaq rules and Rule 10A-3 of the Exchange Act.
  • Committee assignments (current):
    • Audit Committee: Chair; members John Clarke and Swatick Majumdar (all independent; D’An is financial expert).
    • Compensation Committee: Members D’An and John Clarke; Clarke serves as chair.
  • Tenure/classification: Class III; term expires at 2026 annual meeting.
  • Attendance: In FY ended Mar 31, 2024, she attended 8 of 9 post-closing Board meetings (88.9%) and attended all Audit Committee meetings that year (4 meetings).

Fixed Compensation

Zoomcar’s non-employee director compensation framework and D’An’s actual cash fees:

ItemAmountSource
Annual Board cash retainer$75,000
Committee member retainersAudit: $10,000; Compensation: $6,000; Nominating/Gov: $4,000
Committee chair additional retainersAudit: $10,000; Compensation: $6,000; Nominating/Gov: $4,000
FY 2024 cash fees (Apr 1, 2023–Mar 31, 2024)$97,752
FY 2025 cash fees (Apr 1, 2024–Mar 31, 2025)$101,000

Notes:

  • Fees are paid quarterly in arrears and prorated for partial service periods.

Performance Compensation

Zoomcar grants RSUs to non-employee directors; vesting and award values are below.

MetricPolicy / Award DesignDetails
Initial RSU award (non-Chair)$300,000 grant value
Initial RSU award (Chairman)$400,000 grant value
Annual RSU award$100,000 grant value (if no initial grant in last 12 months)
Vesting1/3 on first anniversary of grant; then quarterly thereafter; service-based
Change-in-controlRSUs accelerate in full upon change-in-control
FY 2025 RSU award (D’An)$5,154 fair value; Black-Scholes $2.92 per RSU

Performance metrics table:

Performance MetricWeightingThreshold/TargetOutcome
None disclosed for director RSUs

Form S-8 and plan capacity context:

  • Form S-8 filed Feb 11, 2025 to register 392,189 shares under the Incentive Plan; shareholders approved a one-time increase equal to 15% of shares outstanding on Mar 31, 2025, adding 369,311 shares; total currently issuable under the Plan is 370,955 shares (company intends to file an additional Form S-8 for the increase).

Other Directorships & Interlocks

CompanyExchange/TickerRolePotential Interlock/Conflict
Backblaze, Inc.NASDAQ: BLZEAudit Chair; Comp memberNo Zoomcar-related transactions disclosed
GHD Group Pty LtdPrivateAudit Chair; I&D and Risk memberNo Zoomcar-related transactions disclosed
Enochian BiosciencesNASDAQ: ENOBFormer DirectorPast role; no current interlock
Summer Infant, Inc.Former NASDAQFormer Director (Comp Chair)Company sold; no current interlock

Expertise & Qualifications

  • Former EY audit partner with extensive SEC reporting and internal controls experience; designated Audit Committee financial expert.
  • Governance leadership: Chairs multiple audit committees; NACD Florida Board Chair; frequent governance speaker.
  • Industry exposure across technology, consumer, and engineering/services, aligning with Zoomcar’s platform business.

Equity Ownership

CategoryAmountAs-of Date
Beneficial ownership (common shares)0 shares (shown as “--” in table)
Beneficial ownership (common shares)0 shares (shown as “--” in table)
RSU awards (FY 2025)$5,154 fair value; $2.92 per RSU (number of RSUs not disclosed)

Notes:

  • No pledging or hedging of Zoomcar stock by D’An disclosed; no director ownership guidelines disclosed for Zoomcar; compliance status not disclosed.
  • Indemnification agreements are in place for directors.

Governance Assessment

  • Strengths

    • Independent director with deep audit and governance credentials; designated financial expert and Audit Committee chair.
    • Active committee service; compensation oversight (member) and audit leadership enhance board effectiveness.
    • Attendance: near-full Board participation post-closing FY 2024 and full Audit Committee attendance, indicating engagement.
  • Watch items

    • Director equity awards accelerate on change-in-control—common in market practice but can be investor-unfriendly if not balanced by robust performance linkage (none disclosed for director RSUs).
    • Beneficial ownership appears minimal (no common shares reported as of Dec 30, 2024); alignment relies on RSU grants rather than open-market holdings.
  • Conflicts/related-party exposure

    • No related-party transactions disclosed involving D’An. Audit Committee reviews related party matters; several company-level related party transactions exist with other parties (e.g., Ananda Trust, Aegis/Cantor/J.V.B.), but none involve D’An.
  • Overall view

    • D’An’s audit expertise and independence are positives for investor confidence. Attendance and committee leadership support effective oversight. Equity alignment is primarily via RSUs; lack of disclosed personal share ownership is neutral-to-slightly negative on “skin in the game,” but typical for many directors.